Deliver the interim analysis data from the Stellar trial of QR-421a
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- March 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“QR-421a Stellar Phase 1/2 trial for Usher syndrome and non-syndromic retinitis pigmentosa interim analysis on track for late Q1/early Q2 2021”
What we found
Evidence strength A What the grades mean
A 2022 20-F says Stellar trial data for ultevursen, which the filings tie to exon 13 Usher/nsRP populations, were presented in March 2021, before the March 31, 2021 deadline.
-
A ProQR Therapeutics N.V. 6-K filed 2021-05-06
“FFB has agreed to provide funding of $7.5 million for the pre-clinical and clinical development of QR-421a for Usher syndrome type 2A targeting mutations in exon 13.” ✓ confirmed on the page
-
A ProQR Therapeutics N.V. 20-F filed 2022-04-29
“In March 2021, we presented data from a Phase 1/2 clinical trial of ultevursen, named Stellar, in adults with Usher syndrome or nsRP due to exon 13 USH2A mutations.” ✓ confirmed on the page
-
A ProQR Therapeutics N.V. 20-F filed 2022-04-29
“In March 2021, results from the Stellar trial were reported.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Deliver
- Deliverable
- QR-421a Stellar trial interim analysis data
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you ProQR Therapeutics N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-PRQR-024605 · Corrections policy